Comparative Pharmacology
Head-to-head clinical analysis: ZYRTEC HIVES versus ZYRTEC D 12 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZYRTEC HIVES versus ZYRTEC D 12 HOUR.
ZYRTEC HIVES vs ZYRTEC-D 12 HOUR
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Selective histamine H1-receptor antagonist. Inhibits histamine-mediated vasodilation, capillary permeability, and smooth muscle contraction.
Cetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the respiratory tract mucosa, causing vasoconstriction and reduced edema.
Relief of symptoms associated with allergic rhinitis (sneezing, rhinorrhea, nasal pruritus, ocular pruritus)Chronic idiopathic urticaria (reduction of pruritus and number/size of wheals)Off-label: Atopic dermatitis, allergic conjunctivitis, and adjunctive therapy for anaphylaxis (post-stabilization)
Symptomatic relief of seasonal allergic rhinitisSymptomatic relief of perennial allergic rhinitisRelief of nasal congestionOff-label: treatment of chronic urticaria
For chronic idiopathic urticaria, adults: 10 mg orally once daily. For intermittent symptoms, up to 10 mg once daily as needed.
1 tablet (5 mg cetirizine / 120 mg pseudoephedrine) orally every 12 hours. Maximum 2 tablets per 24 hours.
None Documented
None Documented
The terminal elimination half-life is approximately 8.3 hours in healthy adults. In patients with renal impairment (CrCl < 40 mL/min), half-life can extend to 18–21 hours, necessitating dose adjustment.
Cetirizine: 8-10 hours in healthy adults; increased in renal impairment (e.g., up to 30 hours in severe impairment). Pseudoephedrine: 5-8 hours (pH-dependent; longer in alkaline urine).
Primarily hepatic via CYP3A4 and CYP2D6; also via metabolism to cetirizine (active); less than 1% excreted unchanged in urine.
Cetirizine undergoes minimal hepatic metabolism (oxidative O-dealkylation) primarily via CYP3A4, with negligible contribution from other CYP enzymes. Pseudoephedrine undergoes partial hepatic metabolism (N-demethylation) and is excreted largely unchanged in urine (70-90%).
Cetirizine is primarily excreted renally as unchanged drug (approximately 70%). Fecal excretion accounts for about 10%. The remainder undergoes hepatic metabolism to inactive metabolites, which are also renally eliminated.
Cetirizine: 70% renal (unchanged), 10% fecal. Pseudoephedrine: 90% renal (unchanged), remainder metabolized and excreted in urine.
Protein binding: 93% bound, primarily to albumin.
Cetirizine: 93% bound (albumin). Pseudoephedrine: negligible (<5%).
Volume of distribution: 0.5–0.8 L/kg, indicating distribution into total body water and some tissue binding.
Cetirizine: 0.3-0.5 L/kg; distributes into extracellular fluid. Pseudoephedrine: 2.6-3.0 L/kg; extensive tissue distribution.
Oral bioavailability: Approximately 70% (range 60–80%), due to incomplete absorption. Food does not significantly affect the extent of absorption.
Cetirizine: 70% (oral). Pseudoephedrine: 100% (oral); first-pass metabolism minimal.
For GFR 30-50 mL/min: reduce dose to 5 mg once daily. For GFR <30 mL/min or end-stage renal disease: contraindicated.
Creatinine clearance 30-49 mL/min: 1 tablet every 24 hours. Creatinine clearance <30 mL/min or ESRD: contraindicated.
Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: reduce dose to 5 mg once daily.
Child-Pugh class A: no adjustment. Child-Pugh class B: 1 tablet every 24 hours. Child-Pugh class C: not recommended.
Children 6-12 years: 5 mg orally once daily; children 2-5 years: 2.5 mg orally once daily; children 6 months to <2 years: 2.5 mg orally once daily.
Not recommended for children under 12 years of age. For children ≥12 years: same as adult.
Elderly patients (≥65 years) with normal renal function: no adjustment; may start at 5 mg once daily if sensitivity is a concern. Monitor for dizziness and sedation.
Initiate at 1 tablet every 24 hours due to increased sensitivity and renal function decline. Monitor for anticholinergic effects and cardiovascular adverse events.
No FDA black box warning.
None.
Somnolence may occur; caution when driving or operating machinery. Avoid concurrent use with alcohol or CNS depressants. Dose adjustment in renal impairment (CrCl < 31 mL/min). Caution in elderly due to increased sensitivity/sedation. May cause urinary retention in patients with prostatic hyperplasia or bladder obstruction.
["Cardiovascular effects: hypertension, palpitations, tachycardia, arrhythmias (especially in patients with pre-existing cardiovascular disease)","CNS stimulation: insomnia, nervousness, dizziness, tremor; avoid use with other sympathomimetics","Urinary retention: caution in patients with prostatic hypertrophy or bladder neck obstruction","Increased intraocular pressure: avoid in narrow-angle glaucoma","Severe hepatic impairment: use with caution; dose adjustment may be necessary","Elderly patients: more sensitive to CNS and cardiovascular effects"]
Hypersensitivity to levocetirizine, cetirizine, or any excipient. End-stage renal disease (CrCl < 10 mL/min) or patients on dialysis. Avoiding use in pregnancy unless clearly needed (category B; limited human data).
["Severe hypertension","Coronary artery disease","Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation","Narrow-angle glaucoma","Urinary retention","Severe renal impairment (CrCl <10 mL/min) for cetirizine component","Hypersensitivity to any component"]
Data Pending Review
Data Pending Review
No significant food interactions. Grapefruit juice does not affect cetirizine metabolism. Alcohol may potentiate CNS depression (drowsiness).
Avoid excessive caffeine (coffee, tea, cola, energy drinks) as it may increase the risk of nervousness and insomnia. No significant food interactions with cetirizine; however, grapefruit juice may affect pseudoephedrine metabolism but clinical relevance is minimal. Alcohol may increase sedation.
Cetirizine is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and there are no adequate and well-controlled studies in pregnant women. First trimester: No evidence of teratogenicity in human data. Second and third trimesters: No specific fetal risks identified, but use only if clearly needed.
Cetirizine (pseudoephedrine): First trimester: Limited human data, animal studies show no teratogenicity, but pseudoephedrine is a vasoconstrictor; risk of fetal hypoxia. Second/third trimester: Pseudoephedrine may cause uterine artery vasoconstriction, reducing placental perfusion; avoid near term due to risk of neonatal irritability.
Cetirizine is excreted in human breast milk at low concentrations. The milk-to-plasma ratio is approximately 0.25-0.43. Doses up to 10 mg daily are considered compatible with breastfeeding. Monitor infant for drowsiness or irritability.
Cetirizine: Excreted into breast milk (M/P ratio ≈ 0.25-0.5); low risk. Pseudoephedrine: Excreted into breast milk (M/P ratio ≈ 2.6-3.5); may cause infant irritability; avoid if possible.
No dose adjustment is typically required for cetirizine during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) are minimal and do not necessitate dose modification. Standard adult dose of 10 mg once daily is appropriate.
No standard dose adjustment for cetirizine/pseudoephedrine in pregnancy. Use lowest effective dose and shortest duration (max 5-7 days). Pseudoephedrine may have reduced efficacy due to increased clearance in pregnancy; avoid if severe hypertension or preeclampsia.
Category C
Category C
ZYRTEC HIVES (cetirizine) is a second-generation antihistamine indicated for chronic idiopathic urticaria. Unlike first-generation antihistamines, it is less sedating due to reduced CNS penetration. Onset of action is within 1 hour, with duration of 24 hours. For patients with renal impairment (CrCl <30 mL/min), reduce dose to 5 mg once daily. Avoid in patients with severe liver disease. Cetirizine is a metabolite of hydroxyzine; cross-sensitivity may occur. It does not prevent or treat anaphylaxis.
ZYRTEC-D 12 HOUR (cetirizine/pseudoephedrine) combines a second-generation antihistamine with a sympathomimetic decongestant. Avoid in severe hypertension, coronary artery disease, or narrow-angle glaucoma. Use with caution in hyperthyroidism, diabetes, or prostatic hypertrophy. Cetirizine is renally eliminated; adjust dose in renal impairment (CrCl <30 mL/min: use 5 mg once daily). Pseudoephedrine may cause insomnia, nervousness, or elevated blood pressure. Do not exceed recommended dose or use with other products containing alpha-1 agonists.
Take once daily with or without food for hives relief.Avoid alcohol as it may increase drowsiness.Do not exceed recommended dose; overdose may cause severe drowsiness.Seek emergency if hives are accompanied by swelling of face/lips, difficulty breathing, or anaphylaxis.Do not use for acute asthma attacks.Discontinue and consult doctor if symptoms persist beyond 6 weeks.Store at room temperature away from moisture and heat.
Take this medication by mouth with or without food, but always with a full glass of water.Do not crush or chew the tablet; swallow it whole.Avoid driving or operating machinery until you know how cetirizine affects you; it may cause drowsiness.Do not take within 14 days of MAO inhibitors or with other decongestants.Limit caffeine intake as pseudoephedrine may cause jitteriness or insomnia.Contact your doctor if you experience rapid or irregular heartbeat, chest pain, or difficulty urinating.